中华外科杂志
中華外科雜誌
중화외과잡지
CHINESE JOURNAL OF SURGERY
2012年
1期
57-61
,共5页
黄奇迪%胡孝渠%万丽%高国辉%郑书荣%尤捷%郭贵龙
黃奇迪%鬍孝渠%萬麗%高國輝%鄭書榮%尤捷%郭貴龍
황기적%호효거%만려%고국휘%정서영%우첩%곽귀룡
乳腺肿瘤%预后%免疫组织化学%聚合酶链反应
乳腺腫瘤%預後%免疫組織化學%聚閤酶鏈反應
유선종류%예후%면역조직화학%취합매련반응
Breast neoplasms%Prognosis%Immunohistochemistry%Polymerase chain reaction
目的 分析CC3/TIP30蛋白在乳腺癌中的表达及临床意义,并探讨CC3/TIP30与HER-2/neu的mRNA相关性.方法 采用免疫组化EnVision二步法检测2004年1月至2005年1月手术治疗并病理证实的112例乳腺癌标本中CC3/TIP30、HER-2/neu蛋白的表达,分析其表达与临床病理特征及预后的相关性,同时应用化学合成靶向敲除CC3/TIP30 mRNA的siRNA,并转染SK-BR-3细胞株48 h后,应用real-time PCR法测定CC3/TIP30、HER-2/neu基因mRNA的表达水平.结果 免疫组化显示CC3/TIP30蛋白在乳腺癌组织中表达与TNM分期、淋巴结转移、HER-2和分子分型相关(P=0.048、0.019、0.027、0.011),而与患者年龄、肿瘤大小,以及雌激素受体和孕激素受体表达状态无关.实时定量PCR结果示CC3/TIP30 siRNA转染导致CC3/TIP30 mRNA的表达下降,同时伴随着HER-2/neu基因mRNA水平的下降,差异有统计学意义(F=56.797,F=165.101;P均=0.000).分子分型为HER-2阳性型的乳腺癌患者中CC3/TIP30蛋白表达阳性、阴性组患者5年总生存率差异有统计学意义(X2=10.732,P=0.001).结论 CC3/TIP30蛋白表达缺失与乳腺癌的发生、发展有关,提示乳腺癌患者早期发生转移复发可能,可作为HER-2阳性型乳腺癌亚组分型的指标之一.
目的 分析CC3/TIP30蛋白在乳腺癌中的錶達及臨床意義,併探討CC3/TIP30與HER-2/neu的mRNA相關性.方法 採用免疫組化EnVision二步法檢測2004年1月至2005年1月手術治療併病理證實的112例乳腺癌標本中CC3/TIP30、HER-2/neu蛋白的錶達,分析其錶達與臨床病理特徵及預後的相關性,同時應用化學閤成靶嚮敲除CC3/TIP30 mRNA的siRNA,併轉染SK-BR-3細胞株48 h後,應用real-time PCR法測定CC3/TIP30、HER-2/neu基因mRNA的錶達水平.結果 免疫組化顯示CC3/TIP30蛋白在乳腺癌組織中錶達與TNM分期、淋巴結轉移、HER-2和分子分型相關(P=0.048、0.019、0.027、0.011),而與患者年齡、腫瘤大小,以及雌激素受體和孕激素受體錶達狀態無關.實時定量PCR結果示CC3/TIP30 siRNA轉染導緻CC3/TIP30 mRNA的錶達下降,同時伴隨著HER-2/neu基因mRNA水平的下降,差異有統計學意義(F=56.797,F=165.101;P均=0.000).分子分型為HER-2暘性型的乳腺癌患者中CC3/TIP30蛋白錶達暘性、陰性組患者5年總生存率差異有統計學意義(X2=10.732,P=0.001).結論 CC3/TIP30蛋白錶達缺失與乳腺癌的髮生、髮展有關,提示乳腺癌患者早期髮生轉移複髮可能,可作為HER-2暘性型乳腺癌亞組分型的指標之一.
목적 분석CC3/TIP30단백재유선암중적표체급림상의의,병탐토CC3/TIP30여HER-2/neu적mRNA상관성.방법 채용면역조화EnVision이보법검측2004년1월지2005년1월수술치료병병리증실적112례유선암표본중CC3/TIP30、HER-2/neu단백적표체,분석기표체여림상병리특정급예후적상관성,동시응용화학합성파향고제CC3/TIP30 mRNA적siRNA,병전염SK-BR-3세포주48 h후,응용real-time PCR법측정CC3/TIP30、HER-2/neu기인mRNA적표체수평.결과 면역조화현시CC3/TIP30단백재유선암조직중표체여TNM분기、림파결전이、HER-2화분자분형상관(P=0.048、0.019、0.027、0.011),이여환자년령、종류대소,이급자격소수체화잉격소수체표체상태무관.실시정량PCR결과시CC3/TIP30 siRNA전염도치CC3/TIP30 mRNA적표체하강,동시반수착HER-2/neu기인mRNA수평적하강,차이유통계학의의(F=56.797,F=165.101;P균=0.000).분자분형위HER-2양성형적유선암환자중CC3/TIP30단백표체양성、음성조환자5년총생존솔차이유통계학의의(X2=10.732,P=0.001).결론 CC3/TIP30단백표체결실여유선암적발생、발전유관,제시유선암환자조기발생전이복발가능,가작위HER-2양성형유선암아조분형적지표지일.
Objective To explore the clinical significance of CC3/TIP30 protein's expression in breast carcinoma and its correlation with HER-2/neu.Methods The expression of CC3/TIP30 and HER-2/neu protein was detected in 112 breast cancer tissues which was collected from January 2004 to January 2005 by immunohistochemistry and the relationship with clinic pathological parameters and prognosis was analyzed.Small interfering RNA (siRNA) which target to knock out CC3/TIP30 were transfected into SK-BR-3 cells.Real-time PCR were used to detect the level of CC3/TIP30 and HER-2/neu mRNA.Results The results of immunohistochemistry showed CC3/TIP30 protein was correlated with TNM stage,lymph node status,HER-2 status and molecule classification ( P =0.048,0.019,0.027,0.011 ),but there was no association with age,tumor size,estrogen receptor and progesterone receptor.Real-time PCR results revealed that CC3/TIP30 siRNA down-regulation the level of its mRNA,accompanied by a decline in the expression of HER-2/neu gene mRNA,the difference was statistically significant ( F =56.797,P =0.000 ;F =165.101,P =0.000).In addition,Kaplan-Meier curves of disease-specific survival analysis showed a marked difference in the subtype of HER-2 protein positive between CC3/TIP30 positive group and negative group ( x2 =10.732,P =0.001 ).Conclusions The loss of CC3/TIP30 is related to occurrence and development in breast cancer,suggesting early onset of metastasis and recurrence.Perhaps CC3/TIP30 can be considered as a sub-typing indicator in HER-2 positive breast cancer.